MX379513B - Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. - Google Patents

Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.

Info

Publication number
MX379513B
MX379513B MX2018011992A MX2018011992A MX379513B MX 379513 B MX379513 B MX 379513B MX 2018011992 A MX2018011992 A MX 2018011992A MX 2018011992 A MX2018011992 A MX 2018011992A MX 379513 B MX379513 B MX 379513B
Authority
MX
Mexico
Prior art keywords
compositions
methods
aminopurine compounds
treatment therewith
substituted aminopurine
Prior art date
Application number
MX2018011992A
Other languages
English (en)
Spanish (es)
Other versions
MX2018011992A (es
Inventor
Dan Zhu
David Mikolon
Ellen Filvaroff
Gordon L Bray
Heather Raymon
John F Boylan
Lilly L Wong
Robert Hubbard
Suichan Xu
Tam M Tran
Tao Shi
Toshiya Tsuji
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of MX2018011992A publication Critical patent/MX2018011992A/es
Publication of MX379513B publication Critical patent/MX379513B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2018011992A 2016-04-01 2017-03-31 Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. MX379513B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317412P 2016-04-01 2016-04-01
PCT/US2017/025252 WO2017173206A1 (en) 2016-04-01 2017-03-31 Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith

Publications (2)

Publication Number Publication Date
MX2018011992A MX2018011992A (es) 2019-01-24
MX379513B true MX379513B (es) 2025-03-11

Family

ID=59959573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011992A MX379513B (es) 2016-04-01 2017-03-31 Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos.

Country Status (15)

Country Link
US (1) US10576085B2 (OSRAM)
EP (1) EP3436018A4 (OSRAM)
JP (1) JP7014731B2 (OSRAM)
KR (1) KR102356433B1 (OSRAM)
CN (1) CN109069512B (OSRAM)
AU (1) AU2017241837B2 (OSRAM)
BR (1) BR112018070163A2 (OSRAM)
CA (1) CA3018986A1 (OSRAM)
CL (1) CL2018002787A1 (OSRAM)
EA (1) EA039392B1 (OSRAM)
IL (1) IL262007B2 (OSRAM)
MX (1) MX379513B (OSRAM)
NZ (1) NZ746554A (OSRAM)
SG (2) SG11201808388QA (OSRAM)
WO (1) WO2017173206A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
TWI757256B (zh) 2015-11-02 2022-03-11 美商纜圖藥品公司 轉染過程重排之抑制劑
KR102359735B1 (ko) 2016-03-31 2022-02-08 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
KR102359743B1 (ko) 2016-03-31 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌 유도체
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
PT3436019T (pt) 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos
SG11201808237UA (en) 2016-04-01 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
BR112019024311A2 (pt) 2017-05-22 2020-07-28 Janssen Pharmaceuticals, Inc. derivados de indolina substituídos como inibidores da replicação viral do dengue
CN111432841A (zh) 2017-10-04 2020-07-17 细胞基因公司 顺式-4-[2-{[(3s,4r)-3-氟噁烷-4-基]氨基}-8-(2,4,6-三氯苯胺基)-9h-嘌呤-9-基]-1-甲基环己烷-1-甲酰胺的组合物和使用方法
JP7422084B2 (ja) 2018-04-03 2024-01-25 ブループリント メディシンズ コーポレイション Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤
EP3833372A4 (en) * 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
AU2020257207A1 (en) * 2019-04-16 2021-11-25 Vivace Therapeutics, Inc. Bicyclic compounds
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
EP4061364A4 (en) * 2019-11-20 2023-09-13 Vivace Therapeutics, Inc. HETEROARYL COMPOUNDS
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
TW202202498A (zh) * 2020-07-01 2022-01-16 大陸商四川海思科製藥有限公司 一種並環雜環衍生物及其在醫藥上的應用
KR102664454B1 (ko) * 2021-08-03 2024-05-09 한국생명공학연구원 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용
CN114681456A (zh) * 2022-02-23 2022-07-01 中山大学附属第六医院 Plx3397在结直肠癌的治疗中的用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
DE602004025504D1 (de) * 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
US7759342B2 (en) 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US20070225304A1 (en) * 2005-09-06 2007-09-27 Pharmacopeia Drug Discovery, Inc. Aminopurine derivatives for treating neurodegenerative diseases
EP1951693A4 (en) 2005-11-18 2012-05-30 Astrazeneca Ab SOLID FORMULATIONS
CA2652263A1 (en) 2006-05-12 2007-11-22 Myriad Genetics, Inc. Therapeutic compounds and their use in cancer
TWI398252B (zh) 2006-05-26 2013-06-11 Novartis Ag 吡咯并嘧啶化合物及其用途
NZ589053A (en) 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9466042B2 (en) 2012-01-24 2016-10-11 International Business Machines Corporation Facilitating the design of information technology solutions
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
CN113248506A (zh) * 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法
CN115131834A (zh) * 2015-08-13 2022-09-30 小米科技有限责任公司 移动设备及其屏幕模组、指纹采集方法、装置及电子设备
PT3436019T (pt) * 2016-04-01 2021-11-04 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetra-hidro-2h-piran-4- il)amino)-8-((2,4,6-triclorofenil)amino)-9h-purin-9-il)-1- metilciclo-hexano-1-carboxamida e métodos de utilização dos mesmos

Also Published As

Publication number Publication date
BR112018070163A2 (pt) 2019-01-29
JP2019510066A (ja) 2019-04-11
IL262007A (en) 2018-10-31
KR20180126497A (ko) 2018-11-27
IL262007B2 (en) 2023-04-01
EA201892229A1 (ru) 2019-03-29
CN109069512B (zh) 2022-06-14
CN109069512A (zh) 2018-12-21
US10576085B2 (en) 2020-03-03
KR102356433B1 (ko) 2022-01-27
WO2017173206A1 (en) 2017-10-05
CL2018002787A1 (es) 2019-01-18
EP3436018A1 (en) 2019-02-06
NZ746554A (en) 2023-03-31
MX2018011992A (es) 2019-01-24
SG11201808388QA (en) 2018-10-30
EA039392B1 (ru) 2022-01-21
US20170281633A1 (en) 2017-10-05
JP7014731B2 (ja) 2022-02-01
AU2017241837A1 (en) 2018-10-25
EP3436018A4 (en) 2019-11-13
CA3018986A1 (en) 2017-10-05
IL262007B (en) 2022-12-01
AU2017241837B2 (en) 2021-07-22
SG10202009589UA (en) 2020-10-29

Similar Documents

Publication Publication Date Title
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2022005780A (es) Moduladores de receptores estrogenicos.
MX2021003478A (es) Compuestos utiles como inhibidores de cinasa.
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
EA201890857A1 (ru) Соединения, применимые в качестве иммуномодуляторов
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
AU2016256469A8 (en) Methods for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
PH12018500423A1 (en) Inhibitors of ezh2
PH12017501879A1 (en) Methods for treating cancer
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
PH12021552389A1 (en) Quinoline derivatives and their use for the treatment of cancer
MX2021009195A (es) Metodos y composiciones para el tratamiento del cancer.